---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-209044"
form_type: "8-K"
ticker: "INVA"
cik: "0001080014"
company_name: "Innoviva, Inc."
filed_at: "2026-05-06T23:59:59+00:00"
generated_at: "2026-05-14T22:28:31.839296+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Innoviva Q1 revenue $98M (+11% YoY); IST sales surge 37%; net income $186.6M

## Summary
- Total revenue $98.0M, up 11% YoY; GSK royalty revenue $58.6M (down from $61.3M).
- Net product sales $41.4M (+37% YoY); US sales $34.2M led by GIAPREZA $19.7M, XACDURO $11.6M.
- Net income $186.6M ($2.52 EPS) driven by $191.2M favorable fair value change in equity investments, primarily Armata Pharmaceuticals.
- Repurchased 971,066 shares for $20.4M in Q1 under $125M share repurchase program.
- NUZOLVENCE (zoliflodacin) FDA-approved Dec 2025; availability expected H2 2026.

## SEC filing metadata
- accession: 0001193125-26-209044
- form_type: 8-K
- ticker: INVA
- cik: 0001080014
- company_name: Innoviva, Inc.
- filed_at: 2026-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1080014/000119312526209044/0001193125-26-209044-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1080014/000119312526209044/d54063d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-209044
- JSON: https://secwatch.observer/filing/0001193125-26-209044.json
- Plain text: https://secwatch.observer/filing/0001193125-26-209044.txt

## Key facts
- Earnings Releases
  Innoviva, Inc. reported first quarter ended March 31, 2026 results: revenue $98.0 million, net income $186.6 million, EPS $2.52 basic earnings per share.
  - Period: first quarter ended March 31, 2026
  - Revenue: $98.0 million
  - Net income: $186.6 million
  - EPS: $2.52 basic earnings per share
  - Result: reported results
  source text: and long-term shareholder value creation throughout variable market environments,” concluded Mr. Raifeld. Financial Highlights for the First Quarter of 2026 • Total revenue: $98.0 million, yielding 11% growth compared to $88.6 million for the first quarter 2025. • Royalty revenue: gross royalty revenue from Glaxo Group Limited (“GSK”) was $58.6 million, compared
  evidence_url: https://www.sec.gov/Archives/edgar/data/1080014/000119312526209044/0001193125-26-209044-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.